DexCom’s (DXCM) Overweight Rating Reiterated at JPMorgan Chase & Co.

DexCom (NASDAQ:DXCM)‘s stock had its “overweight” rating reaffirmed by JPMorgan Chase & Co. in a research note issued on Thursday, The Fly reports. They presently have a $215.00 target price on the medical device company’s stock, up from their prior target price of $190.00. JPMorgan Chase & Co.‘s price objective points to a potential upside of 8.54% from the stock’s previous close.

Other analysts have also issued research reports about the stock. BMO Capital Markets lifted their price objective on shares of DexCom from $180.00 to $190.00 and gave the company an “outperform” rating in a research note on Tuesday, September 3rd. Bank of America lifted their price objective on shares of DexCom from $162.00 to $185.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Canaccord Genuity lifted their price objective on shares of DexCom from $160.00 to $185.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Piper Jaffray Companies set a $182.00 price objective on shares of DexCom and gave the company a “buy” rating in a research note on Monday, September 23rd. Finally, Oppenheimer lifted their price objective on shares of DexCom from $167.00 to $180.00 in a research note on Thursday, August 1st. Five research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. DexCom has an average rating of “Buy” and an average price target of $190.67.

Shares of DexCom stock traded up $3.38 during midday trading on Thursday, hitting $198.08. 2,580,200 shares of the company traded hands, compared to its average volume of 1,138,483. The stock has a market cap of $14.00 billion, a price-to-earnings ratio of 660.27 and a beta of 0.64. DexCom has a 12 month low of $105.05 and a 12 month high of $200.80. The company has a debt-to-equity ratio of 1.56, a quick ratio of 5.64 and a current ratio of 6.05. The firm’s fifty day moving average price is $155.57 and its 200-day moving average price is $146.29.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, November 6th. The medical device company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.45. The company had revenue of $396.30 million during the quarter, compared to analyst estimates of $348.99 million. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. DexCom’s revenue for the quarter was up 48.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.17 EPS. Equities research analysts forecast that DexCom will post 0.94 earnings per share for the current year.

In other DexCom news, Director Nicholas Augustinos sold 1,208 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $185.29, for a total transaction of $223,830.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Andrew K. Balo sold 9,107 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $151.56, for a total transaction of $1,380,256.92. The disclosure for this sale can be found here. Insiders have sold a total of 105,222 shares of company stock valued at $16,407,406 in the last 90 days. 1.80% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in the business. First Allied Advisory Services Inc. bought a new stake in DexCom during the 3rd quarter valued at $271,000. Lyell Wealth Management LP bought a new stake in DexCom during the 3rd quarter valued at $2,999,000. BBVA USA Bancshares Inc. bought a new stake in DexCom during the 3rd quarter valued at $470,000. Massachusetts Financial Services Co. MA increased its stake in DexCom by 9.0% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 200,499 shares of the medical device company’s stock valued at $29,922,000 after purchasing an additional 16,568 shares in the last quarter. Finally, Tower Research Capital LLC TRC bought a new stake in DexCom during the 3rd quarter valued at $205,000. Institutional investors and hedge funds own 96.19% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: What is the Rule of 72?

The Fly

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.